1Silver J, Kilav R, Naveh - Many T. Mechanisms of secondary hyper parathyroidism. Am J Physiol Renal Physiol, 2002,283: F367 - F376
2Ganesh SK, Stack AG, Lewin NW, et al. Association of elevated serum PO( 4), CaXPO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients L Am J Soc Nephrol, 2001,12:2131 - 2138
3Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant, 2004, 19 Suppl 5:v15 - v19
4National Kidney Foundation. Kidney Disease Qality Outcomes Initiative (K/DOQI) clinical prictice guidlines. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003, 42 ( Suppl 3): S1 - S20
5Goodman. W G. Recent developments in the management of secondary hyperparathyroidism. Kidney Int,2001,59:1187 - 1201
6Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: rationale for using results from clinical trials. Pediatr Nephrol, 2003, 18 (12): 1206 - 10
7Torres P U. Clinical experience with cinacalcet HCL. Nephrol Dial Transplant, 2004, 19[Suppl 5]: v27 - v33
8Wada M, Nagano N. Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transplant, 2003, Suppl 3:12
9Cunningham J. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism. Nephrol Dial Transplant, 2004, 19 Suppl 5: v9- v14
10Block GA,Martin KJ,de Fracisco AL,et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med, 2004,350(15): 1516 - 25
